Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kei I am with you on BLPH.
Yeah I know. Was in PWTC in like 98. Lost my but. I bought 2m shares just before the rs. I still holding. 200 shares I think. My father in law actually went to Las Vegas and met Alan Snapper. Sad story what happened with them.
BLPH. I Avg down again. Looking strong. Data coming any day.
Once upon a time there was a company.....
PTX nice day. Closer to buy out? BLPH on watch. I am long both.
VSTM At $1.2 With Over $2/share Cash And Phase 3 Topline Data In June Is Deeply Undervalued. Analysts PT $3.3/Share
Mar. 8, 2017 1:29 PM
Investment Highlights:....long SA post. Go there to get it.
Nice day but I am no where close to even. Hopefully the pH 2 results are good.
BLPH moving up on heavy volume.
FBR lists prime takeover candidates in biotech
Mar. 6, 2017 9:13 AM • SA Editor Douglas W. House
FBR's Chris Meekins says the potential for tax reform and FDA policy changes could stoke biotech M&A activity.
His short list of leading takeover candidates: TESARO (NASDAQ:TSRO), Agile Therapeutics (NASDAQ:AGRX); Kite Pharma (NASDAQ:KITE), Juno Therapeutics (NASDAQ:JUNO); Acceleron Pharma (NASDAQ:XLRN); Aurinia Pharmaceuticals (NASDAQ:AUPH), Geron (NASDAQ:GERN) and Genocea (NASDAQ:GNCA).
Source: StreetInsider
Up PM on very little volume. Can we close over 4 today?
Looking at 3 13g this year. 65% ownership. One person has 55%. POLA. Only about 9m OS and they just raised 17m.
BLPH and PTX up PM.
PTX. Check out @jh1429 message on StockTwits http://stocktwits.com/jh1429/message/76300742
Fed hike coming. Stocks posted weekly gains Friday, while Federal Reserve Chair Janet Yellen put an exclamation point on the possibility of a rate hike this month.
"I think Janet Yellen has done a good job of walking the tightrope of preparing the market for this," said Ben Baier, senior portfolio manager at Bank of the West. "It would take something big to knock them off this rate hike."
While leaving just enough wiggle room in case conditions should change, the central bank leader said economic improvements of late will be a big part of the discussion at the March 14-15 Federal Open Market Committee meeting.
"With the Fed, we're going from red to green; there's no yellow," said Tom Siomades, head of Hartford Funds Investment Consulting Group. But "they haven't been very overt in terms of action. It's always been a wait-and see Fed, and that's what makes people nervous."
More like a MM taking out stop losses.
KeI. PTX is running!
Isn't this the old PWTC stock?
Kei BLPH http://archive.fast-edgar.com//20170301/A42L3Q2CZZ2RRZZK22TR2ZXPS4KQZZ22Z292/
I have held this over a year. First paid 4 something. I averaged down some last week.
MORRISTOWN, N.J., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company with a focus on Pain and CNS conditions, announced today that it received a favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER. Judge Gregory M. Sleet of the United States District Court for the District of Delaware concluded that Actavis’ proposed generic versions of Zohydro ER infringe U.S. Patent Nos. 9,132,096 (which expires on September 12, 2034) and 6,902,742 (which expires on November 1, 2019) following a trial that took place in October 2016. The Judge has entered an order enjoining Actavis from engaging in the commercial manufacture, use, offer to sell, or sale in the United States, or importation into the United States of Actavis’ Abbreviated New Drug Application (ANDA) product prior to expiration of the two patents. Actavis did not assert invalidity or unenforceability of the patents at trial.
“We are pleased with the Court’s decision as it confirms the strength and longevity of the Zohydro ER patent portfolio,” said John Sedor, Chairman and CEO of Pernix. “Zohydro ER is a core component of our product portfolio and we look forward to driving continued growth of the franchise.”
Both patents are listed in the FDA’s “Orange Book” for Zohydro ER and are licensed to Pernix by Recro Gainesville LLC. Recro and another generic pharmaceutical manufacturer, Alvogen Malta Operations Ltd., filed a stipulation of dismissal last year ending a patent infringement lawsuit Recro filed against Alvogen concerning its proposed generic version of Zohydro ER.
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and pain management, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its integrated Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Matthew P. Duffy, 212-915-0685
LifeSci Advisors, LLC
matthew@lifesciadvisors.com
Ha NASA did discover 7 new planets today. Only 40 light years away!
I hope so because I own it at a multiple of today's price!
Check out @humboldt111502 message on StockTwits http://stocktwits.com/humboldt111502/message/75328916
Watch PTX. Finally moving up. Strong buy out candidate. Per SEC filings they are accepting bids. Info on ST.
This board doesn't need moderated the company needs moderated.
DCTH.If that is the case they have diluted about 9 m. Now we know where the high volume days came from.
PTGEF up again on unusual volume.
No. I agree.
PTGEF up again today?
Like rip van winkle
I know. I just want a commitment from him since he knows so much.
When , give me a date.
A lot of people subtract the debt from that?